Related Experiment Videos
Drug-eluting stents: are they really safe?
Renu Virmani1, Frank D Kolodgie, Andrew Farb
1Department of Cardiovascular Pathology, Armed Forces Institute of Pathology, 6825 16th Street NW, Washington, DC 20306-6000, USA. virmani@afip.osd.mil
The American Heart Hospital Journal
|December 18, 2004
Summary
Drug-eluting stents show delayed healing and incomplete endothelial coverage, potentially increasing risks like stent thrombosis. Caution and further surveillance are advised for these devices.
Area of Science:
- Cardiovascular Medicine
- Biomaterials Science
Background:
- Drug-eluting stents (DES) have improved outcomes by reducing in-stent restenosis.
- Current data primarily reflects outcomes in simple lesions and non-complex patients.
Purpose of the Study:
- To evaluate the long-term healing response and potential complications associated with drug-eluting stents.
- To compare healing profiles of DES versus bare-metal stents in preclinical and human studies.
Main Methods:
- Preclinical studies in pigs and rabbits comparing bare-metal stents and DES healing at 28 days.
- Analysis of human autopsy and atherectomy specimens at 6 and 12 months post-DES implantation.
- Review of adverse event data from regulatory agencies and author's autopsy findings.
Main Results:
- Bare-metal stents demonstrated complete healing, while DES showed persistent fibrin and incomplete endothelial coverage.
- Delayed healing was observed in human specimens at 6 and 12 months.
- Adverse events including subacute thrombosis, hypersensitivity reactions, late stent thrombosis, aneurysm formation, and inflammation were noted.
Conclusions:
- Drug-eluting stents may exhibit delayed healing and incomplete endothelialization, posing risks of thrombosis and inflammatory reactions.
- Clinical use of DES warrants caution, emphasizing the need for systemic therapies, enhanced postmarket surveillance, and histologic examination.